Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 9/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995228 | 1.00 | EIF2AK4 (0.44) | EIF2AK4EGFRBTKITKHDAC4 | |
| SCHEMBL1993982 | 0.93 | EIF2AK4 (0.43) | EIF2AK4EGFRBTKITKHDAC4 | |
| SCHEMBL1994797 | 0.92 | EIF2AK4 (0.46) | EIF2AK4HDAC4HDAC6USP30 | |
| SCHEMBL15198112 | 0.92 | EIF2AK4 (0.46) | EIF2AK4HDAC4HDAC6USP30 | |
| SCHEMBL2053807 | 0.92 | EIF2AK4 (0.42) | EIF2AK4BTKHDAC4HDAC6USP30 | |
| SCHEMBL15193374 | 0.92 | EIF2AK4 (0.42) | EIF2AK4EGFRBTKITKHDAC4 | |
| SCHEMBL15193373 | 0.92 | EIF2AK4 (0.42) | EIF2AK4EGFRBTKITKHDAC4 | |
| SCHEMBL15193921 | 0.92 | EIF2AK4 (0.42) | EIF2AK4BTKHDAC4HDAC6USP30 | |
| SCHEMBL15193920 | 0.92 | EIF2AK4 (0.42) | EIF2AK4BTKHDAC4HDAC6USP30 | |
| SCHEMBL15194021 | 0.91 | EIF2AK4 (0.42) | EIF2AK4BTKHDAC4HDAC6USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | EIF2AK4 211/4885EGFR 352/4885BTK 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.